ALLO
Allogene Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.97
−0.51%Margins
Gross margin
-699.4%
EBITDA margin
-3287.2%
EBIT margin
-3886.1%
Net margin
-3566.7%
FCF margin
-2211.2%
-37.9%
Return on equity
-30.1%
Return on assets
-35.6%
Return on invested capital
0.01x
Asset turnover
-$102.2M
Cash from operations
$0.96
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026